The Next Challenge: Improving And Predicting Responses As CAR-T Therapies Advance

Chimeric antigen receptor T cell (CAR-T) therapies have shown unprecedented response rates and may extend survival for patients expected to live only a few more months. Now, CAR-T developers are looking at how to improve responses, extend survival and improve safety.

Now that investigators have shown promising efficacy for chimeric antigen receptor T cell (CAR-T) therapies in patients who've run out of options, researchers and biopharmaceutical companies are trying to understand why some patients stop responding while others don't respond at all.

CAR-T cell persistence, loss of the targeted antigen and emergence of treatment-resistant mechanisms are areas of interest. Combining CAR-T therapies...